NewAmsterdam Pharma (NASDAQ:NAMS) Short Interest Update

NewAmsterdam Pharma (NASDAQ:NAMS) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 4,340,000 shares, an increase of 42.8% from the February 28th total of 3,040,000 shares. Approximately 7.5% of the shares of the stock are short sold. Based on an average daily trading volume, of 843,800 shares, the short-interest ratio is presently 5.1 days.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. UBS Group set a $41.00 price objective on NewAmsterdam Pharma in a research note on Monday, March 3rd. Scotiabank increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a “sector outperform” rating in a report on Thursday, February 27th. Needham & Company LLC dropped their target price on shares of NewAmsterdam Pharma from $46.00 to $42.00 and set a “buy” rating for the company in a research note on Thursday, February 27th. Royal Bank of Canada reiterated an “outperform” rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, HC Wainwright restated a “buy” rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $43.33.

Insider Transactions at NewAmsterdam Pharma

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $20.37, for a total transaction of $3,055,500.00. Following the completion of the transaction, the chief accounting officer now directly owns 15,000 shares of the company’s stock, valued at $305,550. This trade represents a 90.91 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director James N. Topper acquired 1,135 shares of the firm’s stock in a transaction on Wednesday, March 26th. The shares were purchased at an average cost of $22.49 per share, for a total transaction of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares of the company’s stock, valued at approximately $67,775,166.81. The trade was a 0.04 % increase in their position. The disclosure for this purchase can be found here. 19.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in the stock. GF Fund Management CO. LTD. bought a new stake in shares of NewAmsterdam Pharma in the 4th quarter valued at about $50,000. National Bank of Canada FI acquired a new position in NewAmsterdam Pharma during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in NewAmsterdam Pharma in the fourth quarter valued at approximately $80,000. Quarry LP raised its holdings in NewAmsterdam Pharma by 2,469.2% in the third quarter. Quarry LP now owns 6,500 shares of the company’s stock worth $108,000 after purchasing an additional 6,247 shares during the period. Finally, Barclays PLC grew its holdings in shares of NewAmsterdam Pharma by 1,813.4% in the 3rd quarter. Barclays PLC now owns 7,596 shares of the company’s stock valued at $126,000 after buying an additional 7,199 shares during the period. Institutional investors and hedge funds own 89.89% of the company’s stock.

NewAmsterdam Pharma Trading Down 10.2 %

Shares of NASDAQ:NAMS traded down $2.09 during trading on Tuesday, hitting $18.38. 2,585,205 shares of the company’s stock were exchanged, compared to its average volume of 545,463. The firm has a market cap of $2.02 billion, a P/E ratio of -7.07 and a beta of -0.04. The firm has a 50-day moving average price of $21.50 and a two-hundred day moving average price of $21.32. NewAmsterdam Pharma has a 1-year low of $15.19 and a 1-year high of $27.29.

NewAmsterdam Pharma (NASDAQ:NAMS) last issued its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The business had revenue of $12.77 million for the quarter, compared to the consensus estimate of $3.30 million. As a group, research analysts predict that NewAmsterdam Pharma will post -1.75 EPS for the current year.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.